Last reviewed · How we verify
Defekton — Competitive Intelligence Brief
phase 2
carpipramine
D(2) dopamine receptor, D(3) dopamine receptor
Other
Small molecule
Live · refreshed every 30 min
Target snapshot
Defekton (CARPIPRAMINE). Defekton works by blocking dopamine receptors in the brain, which can help regulate mood and behavior.
Comparator set (1 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Defekton TARGET | CARPIPRAMINE | phase 2 | carpipramine | D(2) dopamine receptor, D(3) dopamine receptor | ||
| Pramipexole (Mirapex) | Pramipexole (Mirapex) | Massachusetts General Hospital | marketed | Dopamine agonist | D2 dopamine receptor, D3 dopamine receptor |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (carpipramine class)
- · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Defekton CI watch — RSS
- Defekton CI watch — Atom
- Defekton CI watch — JSON
- Defekton alone — RSS
- Whole carpipramine class — RSS
Cite this brief
Drug Landscape (2026). Defekton — Competitive Intelligence Brief. https://druglandscape.com/ci/carpipramine. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing